Fig. 6From: Aberrant Bcl-x splicing in cancer: from molecular mechanism to therapeutic modulationStrategies modulating Bcl-x splicing in cancer. a. An SSO that binds to the proximal 5' splice site (5'PSS) prevents binding of spliceosome, leading to a splicing shift to the short isoform Bcl-xS. b. a. The small molecular modulators that bind to spliceosomal components affect splice-site accessibility, leading to an inhibition of Bcl-xL splicing. c. At the protein level, BH3-mimetics could occupy the hydrophobic pockets of Bcl-Xl, thus blocking their anti-apoptotic activity and resulting in the ignition of apoptosisBack to article page